Is KYTX or LEXX more undervalued in 2026?

CirclFi compares Kyverna Therapeutics, Inc. (KYTX) and Lexaria Bioscience Corp. (LEXX) using 13 institutional-grade valuation models. KYTX has a Quality of Company score of 4.2/10 while LEXX scores 6.7/10.

Which is a better buy — KYTX or LEXX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KYTX and LEXX valuations compare?

KYTX at $8.65 and LEXX at $0.62 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KYTX vs LEXX Valuation Comparison 2026 — Intrinsic Value Analysis

KYTX

Biotechnology

Kyverna Therapeutics, Inc.

Quality

4.2

out of 10

Value Trap

SAFE

Price

$8.65

Last close

Models

7/13

Active

LEXX

Biotechnology

Lexaria Bioscience Corp.

Quality

6.7

out of 10

Value Trap

LOW

Price

$0.62

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	KYTX Fair Value	KYTX Upside	LEXX Fair Value	LEXX Upside
Bayesian DCF	Intrinsic	$2.40	-72.3%	$0.28	-55.3%
Earnings Power Value	Intrinsic	—	—	$0.32	-54.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$2.70	-68.8%	$0.46	-25.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KYTX vs LEXX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KYTX vs LEXX — Which Stock Is More Undervalued?

LEXX scores higher with a 6.7/10 quality rating vs KYTX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kyverna Therapeutics, Inc. (KYTX) and Lexaria Bioscience Corp. (LEXX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KYTX currently trades at $8.65 with a QOC of 4.2/10, while LEXX trades at $0.62 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).